c-Src, at its resting state, is phosphorylated at Tyr-527 and forms an inactive conformation.
Upon activation by extracellular signals, c-Src is dephosphorylated at Tyr-527 and phosphorylated at Tyr-416, and then functions as a tyrosine kinase and a signaling molecule to trigger downstream signal transduction. In contrast, v-Src protein, with a deletion of the C-terminal negative-regulatory region, has lost an autoinhibitory phosphorylation site (Tyr-527) and is constitutively active (1) . v-Src can promote normal cells to acquire a variety of transformation characteristics, including alteration of morphology, loss of contact inhibition, anchorage dependence and growth-factor dependence, and elevation of invasion ability. Oncogenic Src proteins in epithelial cells have been reported to induce a switch between the epithelial and mesenchymal phenotype, the so-called epithelial-mesenchymal transition (EMT) (2) . Oncogenesis induced by v-Src results in aberrant expression or activation of downstream target proteins that are associated with mitogenesis, cell adhesion, motility and angiogenesis (1, 2) . v-Src has been shown to suppress expression of the cell cycle inhibitors (p21 Waf1 and p27 kip1 ) and induce activation of the cyclin/CDK complexes (3, 4) . Elevated expression of the transcription factor c-Myc is required for v-Src transformation of fibroblasts (5) . Active Src also increases the production of matrix metalloproteinases, MMP-2 and MMP-9 (2, 6). Furthermore, down-regulation of the adhesion molecule E-cadherin by v-Src has been observed in several cell types (6) (7) (8) . Expression of v-Src is also required for production of the angiogenesis inducer VEGF (vascular endothelial growth factor) (9) . v-Src protein perturbs multiple intracellular signaling pathways. To date, the PI3 kinase, MAP kinase and STAT-3 signaling pathways have been shown to be essential for v-Src-induced neoplastic transformation (10) . In addition, the signaling pathways required for v-Src-mediated transformation are significantly different between fibroblasts and epithelial cells (11) (12) (13) (14) ).
An elevated Src protein level and activity have been found in many human tumors, such as colon cancers and breast cancers (15) . Furthermore, a truncated mutant of c-Src that is structurally similar to v-Src has been identified in advanced human colon cancer (16) . Therefore, the Src protein has been considered to be a promising chemotherapeutic target and many Src inhibitors have been identified. Most known Src inhibitors restrain the activity of Src by reducing its protein stability, reducing kinase activity or inhibiting protein-protein interactions (17) .
The benzoquinone ansamycins (geldanamycin and herbimycin A) and the macrocyclic antifungal antibiotic (radicicol) have been shown to bind HSP90 and thus reduce Src protein stability (18) . The pyrazolo-pyrimidines (PP1 and PP2) were found to directly inhibit Src tyrosine kinase activity (19) .
In addition, PP2 increases E-cadherin/catenin levels and reduces cancer metastasis in vivo (20) . Another type of Src inhibitor, such as UCS15A, has been shown to disrupt protein-protein interaction, and thus abolish the downstream signal transduction of Src (21) . Nevertheless, only limited Src-targeted drugs have been proven to be efficient in vivo. Currently, there are no Src-specific inhibitors that have clinical application.
In the present study, we established and applied the temperature-inducible v-Src-transformed cell line to identify compounds that inhibit v-Src-mediated cellular transformation. We found that a natural product, andrographolide, significantly suppressed v-Src-induced transformation. Andrographolide is a lactone diterpenoid isolated from the Chinese herb Andrographis paniculata, and has been previously shown to exhibit a wide spectrum of pharmacological activities, such as anti-apoptosis, anti-inflammation, anti-angiogenesis and anti-cancer activity (22) (23) (24) (25) (26) .
The anti-cancer effect of andrographolide was demonstrated by showing its growth-inhibitory activity on various cancer cell lines in vitro and its tumor-suppressive activity in animal models (27) . Andrographolide can induce cell cycle arrest through increasing expression of p27 and decreasing expression of cyclin-dependent kinase 4 (CDK4) (27) . Andrographolide also triggers apoptosis via the caspase-8 dependent pathway in human cancer cells (28) . Through enhancing the cytotoxic T lyphocytes to secret interleukin-2 and interferon-γ, andrographolide inhibits the tumor growth in BALB/c mice (29) . Although these studies reveal the potential of andrographolide in cancer therapy, no reports have described the inhibitory effect of andrographolide on v-Src oncogenicity. In this study, we therefore intended to investigate the molecular mechanism(s) by which andrographolide antagonizes the oncogenic properties of v-Src.
EXPERIMENTAL PROCEDURES
Chemicals and antibodies -Andrographolide, cycloheximide, 4',6-Diamidino-2-phenylindole, p-iodonitrotetrazolium violet and lactacystin were purchased from Sigma Aldrich (St. Louis, MO). Radicicol, PP2, PD98059, ALLN, LY294002, U0126 and STAT-3 peptide inhibitor were purchased form Calbiochem (La Jolla, CA). Texas Red-X phalliodin was purchased from Molecular Probe (Eugene, OR). Sea Plaque agar was purchased from Bio Wittaker Molecular Applications (Rockland, ME). Antibodies against v-Src (clone EC10), Src, phosphotyrosine (clone 4G10), phospho-Akt (Ser473) and ubiquitin were purchased from Upstate Biotechnology (Lake Placid, NY). Anti-E-cadherin, anti-Akt, anti-β-catenin and anti-Erk1 antibodies were purchased from BD Biosciences (San Diego, CA). Anti-phospho-Src (Y416), anti-phospho-Erk1/2 (T202 and Y204) antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-HA antibody was obtained from Convance (Berkely, CA). Anti-Actin and anti-GFP antibodies were purchased from Sigma Aldrich. Plasmids -The retroviral constructs, RCAN (Replication-Competent, ALV-LTR, No splice acceptor) and RCAN-ts-v-src, were kindly provided by Dr. Neil Carragher from the Beatson Institute for Cancer Research, Glasgow, Scotland, United Kingdom. RCAN-v-ts-src encodes a temperature-sensitive v-Src mutant (12) . Both RCAN and RCAN-ts-v-src can produce avian retroviruses of subgroup A in avian cells. The MKK1-CA (MAPKK∆N3/S218E/S222D) plasmid, kindly provided by Dr. Natalie Ahn of the University of Colorado, USA, has been described previously (30) . A 1.5-kb Xba I to Hind III fragment from the MKK1-CA plasmid (encoding a HA-tagged-mutated mkk1 sequence) was first cloned into corresponding sites of PBSFI to yield PBSFI-MKK1-CA. RCAS(A)-MKK1-CA was further created by cloning the SfiI fragment of PBSFI-MKK1-CA into RCASFI, a modified version of the replication-competent retroviral vector RCAS(A) (31) . Cell culture -The ts-v-Src cells (described below) were regularly maintained in Dulbecco's modified Eagle's medium (Biochrom KG, Berlin, Germany) containing 10% fetal bovine serum (Hyclone, Logan, USA), 100 units/ml penicillin, 100 µg/ml streptomycin and 3 µg/ml puromycin (Sigma Aldrich, St. Louis, MO) in a 5% CO 2 humidified incubator at 35 o C or 39.5 o C. The DF-1 cells were cultured as described previously (6) . Creation of a temperature-inducible v-Src-transformed cell line (ts-v-Src cells) -The preparation RCAN-ts-v-src viruses and infection of tv-a-expressing RK3E/tv-a cells have been described previously (6) . The infected cells were maintained for three weeks and tested in focus formation assays and soft agar assays (at 35 o C and 39.5 o C, respectively) using protocols as described previously (6) Soft agar assay -Six-well plates were overlaid with 0.6% nutrient agar (Sea Plaque agar in DMEM with 3% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 3 µg/ml puromycin) before use. The ts-v-Src cells (10 4 ) grown at 39.5 o C were mixed well with 0.3% nutrient agar (Sea Plaque agar in DMEM with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 3 µg/ml puromycin) consisting of vehicle or different concentrations of andrographolide, seeded into prepared six-well plates and transferred to 35 o C. Every 3-4 days, the cells were supplied with 0.3% nutrient agar consisting of vehicle or andrographolide. After two weeks, colonies were stained with 1% (w/v) INT (p-iodonitrotetrazolium violet) solution, photographed and counted. Immunofluorescence and actin cable stainingThe ts-v-src cells were seeded onto cover slips at 39.5 o C. Next day, the cells were incubated with vehicle or andrographolide for 24 hours at 35 o C, fixed with 4% paraformaldehyde for 10 minutes, and subsequently permeablized with 0.5% Triton X-100 for 5 minutes at room temperature. After blocking with 1% BSA/PBS, the cells were incubated with a primary antibody for one hour and then treated with a FITC-conjugated secondary antibody for additional one hour. Then, the cells were stained with 1 µg/ml DAPI (4',6-Diamidino-2-phenylindole) for 10 minutes. The images were detected using a confocal microscope (FV-300, Olympus Corporation, Tokyo, Japan).
To stain actin filaments, the process of fixation and permeablization were conducted as mentioned above. After blocking, the cells were stained with 2.5 units/ml Texas Red-X phalloidin and 1 µg/ml DAPI (4',6-Diamidino-2-phenylindole) for 20 minutes and 10 minutes, respectively. The images were detected using a confocal microscope. For immunoprecipitation, treated cells were collected and lysed in RIPA buffer containing general protease inhibitors. Total protein (300~400 µg) was incubated with anti-v-Src antibody overnight at 4 o C. Protein G sepharose slurry (50 µl) was then added to and reacted with protein/antibody for further 2 hours at 4 o C. Afterwards, the immunoprecipitates were collected by centrifugation for subsequent study. In vitro kinase assay -To determine kinase activity of v-Src, we used a modified procedure based on the instructions of the Universal Tyrosine Kinase Assay Kit (Takara Bio Inc., Shiga, Japan). For each reaction, 10 6 cells were disrupted in extraction buffer and centrifuged for 10 minutes at 10000xg. The immunoprecipitation was then carried out by incubating cell supernatant with anti-v-Src antibody and protein G sepharose. After centrifugation, the immunoprecipitates were washed with 1x PBS containing 0.05%(v/v) Tween-20, resuspended in ATP-supplemented kinase reaction buffer, and incubated with vehicle or drugs for 30 min. The samples were then transferred to wells precoated with peptide substrate for the kinase reaction (30 min, 37 o C), and anti-phosphotyrosine-HRP and HRP substrate were added to each well and incubated for 30 min. After stopping the reaction with 1 N H 2 SO 4 , the absorbance at 450 nm was measured by a microplate photometer (Multiskan RC, Model 351, Lab Systems, Stockholm, Sweden).
Reverse transcriptase-polymerase chain reaction (RT-PCR) -
The ts-v-src cells (10 6 per well) were seeded and grown at 39.5 o C. Next day, the cells were treated with vehicle or drugs, and then incubated for various times at 35 o C. Total RNA isolation and cDNA preparation were conducted as described previously (6) . The sequences of primers used are: (1) o C. Consequently, the cells were incubated with methionine-free medium with 10% dialyzed FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 3 µg/ml puromycin, in the presence of vehicle or drug, for 30 minutes at 35 o C. The [ 35 S]methionine-containing medium [methionine-free medium with 10% dialyzed FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 3 µg/ml puromycin and [ 35 S]methionine (100 µCi per dish)] with vehicle or drug was then supplied to cells for additional 30 minutes incubation at 35 o C. After treatment, cells were harvested, lysed and thus immunoprecipitated with anti-v-Src antibody. Prepared samples were separated by SDS-PAGE and transferred to PVDF membranes. The signals were detected by exposing the membranes directly to X-ray films. Pulse-chase assay -After seeding, the ts-v-src cells were first incubated with methionine-free medium with 10% dialyzed FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 3 µg/ml puromycin for 30 minutes at 39. 
RESULTS

Establishment of a temperature-inducible v-Src-transformed cell line -
In order to identify compounds that interfere with the process of v-Src-induced transformation, we first established a temperature-inducible v-Src-transformed cell line (ts-v-Src cells) by infecting RK3E/tv-a cells with RCAN-v-src-derived avian retrovirus. The RK3E/tv-a is a tv-a-expressing rat kidney epithelial cell line that allows efficient gene delivery via avian retroviral infection (6) . The RCAN-v-src construct contains a temperature-sensitive v-src mutant carrying a point mutation (Ala-to-Pro substitution at residue 507). This mutant has been previously shown to exhibit temperature-dependent kinase activity and transforming ability (32) . We first demonstrated that cellular transformation of ts-v-Src RK3E cells could be regulated by the temperature switch. At the permissive temperature (35 o C), ts-v-Src cells showed a transformed morphology, were able to induce focus formation and had acquired anchorage-independent growth ability. In contrast, ts-v-Src cells grown at the non-permissive temperature (39.5 o C) displayed a typical epithelial morphology and did not induce focus formation or soft-agar colony formation (supplemented data Figure 1) . Andrographolide suppresses v-Src-induced morphological transformation and colony formation -We thus applied ts-v-Src cells for the screening of anti-transformation compounds (all tested compounds are listed in supplemented data Table 1 ). The ts-v-Src cells grown at 39.5 o C were treated with vehicle or natural products, immediately switched to the 35 o C incubator and cultured for 24 hr to identify the natural products that were able to impede the v-Src-induced transformation process. For each tested compound, multiple concentrations were initially tested and sub-lethal dosages were determined for extended studies. Among the natural products examined, only andrographolide exhibited the ability to block the v-Src-induced morphological transformation. As shown in Figure 1 , ts-v-Src-transformed cells grown at 35 o C were more refractile in appearance, had more membrane extensions, showed reduced adhesion and lost cell-cell contact ( Figure  1B ). When different concentrations of andrographolide (1, 3, 5 and 10 µM) were added prior to temperature switch, we found that morphological alteration was inhibited by andrographolide at 5 µM after incubation at 35 o C for 24 hr ( Figure 1F ). The morphology of the andrographolide-treated cells is flat polygonal with clear cell-cell contacts, which is similar to that of non-transformed ts-v-Src cells grown at 39.5 o C ( Figure 1A ). Andrographolide at 3 µM only exhibited a slightly inhibitory effect on the morphological transformation ( Figure  1E ), while andrographolide at 1 µM did not affect the morphological transformation (data not shown). Radicicol, a known v-Src inhibitor, also blocked the v-Src-mediated morphological transformation ( Figure 1D ). In contrast, several well-known natural compounds such as naringenin (a natural citrus flavanone), baicalin (the active ingredient form Scutellaria baicalensis), and camptothecin (a plant-derived anti-tumor agent) did not affect the v-Src-mediated morphological transformation (Figure1 G, H, I).
We also examined whether andorgrapholide could affect anchorage-independent growth ability, another feature of v-Src-transformed cells. The ts-v-Src cells treated with vehicle and andorgrapholide at 1 µM exhibited anchorage-independent growth ability on soft agar. However, andrographolide at 3 µM and 5 µM showed slightly and strongly inhibitory effects on colony formation, respectively. These results indicate that andrographolide can restrain the v-Src-induced transformation in a concentration-dependent manner.
Andrographolide treatment causes the disorganization of actin filaments and delays v-Src-mediated E-cadherin down-regulation in v-Src-transformed cells -
The v-Src activation is known to cause the loss of organized actin filaments (33) . To determine the effect of andrographolide on actin organization, we stained the intracellular actin cables of andrographolide-treated cells with Texas Red-phalloidin. The ts-v-Src cells at 39. Compared with untreated v-Src-transformed cells, cell-cell contact was retained among andrographolide-treated cells. v-Src is known to down-regulate E-cadherin expression, which contributes to the loss of cell-cell contact (6) (7) (8) . Therefore, we further examined whether the expression of E-cadherin was affected by andrographolide. In the control group, the amount of E-cadherin protein declined with increased dosage or incubation time, but the amount of E-cadherin remained unchanged after 12-hour of andrographolide treatment in the test group ( Figure 2B and 2C) . β-catenin, another protein involved in cell-cell adhesion, was also examined but andrographolide did not affect the cellular level of β-catenin ( Figure 2C Figure  3A) . Particularly, the tyrosine phosphorylation levels of several proteins were dramatically reduced. Several known downstream targets of v-Src, such as FAK (120 kDa), CAS (94 kDa), Paxillin (68 kDa), Shc (52 kDa), Annexin II (36kDa) and Caveolin-1 (25 kDa) appear to match the sizes of the altered phosphoproteins.
However, the identity of these phosphoproteins remains to be verified.
Alteration of tyrosine phosphorylation patterns in v-Src-transformed cells by andrographolide treatment may result from the decreased expression of the v-Src protein, or an inhibition of Src kinase activity. We therefore used a universal tyrosine kinase assay to examine whether andrographolide can directly inhibit v-Src kinase activity. As shown in Figure  3B , Figure 4D , the protein synthesis of v-Src was not affected. Therefore, andrographolide did not affect the transcription and translation of v-src, suggesting that this compound may act on v-Src through the post-translational process. Figure 5B , the labeled v-Src protein was decreased in the presence of andrographolide while v-Src protein remains stable after vehicle treatment. These results suggest that andrographolide facilitates v-Src protein degradation.
Ubiquitination of v-Src is involved in andorgrapholide-induced v-Src degradation -
According to previous report, the active Src protein can be degraded in an ubiquitin-dependent manner (39) . Therefore, we examined whether andrographolide attenuated v-Src level via ubiquitin-mediated degradation. Although andrographolide treatment did slightly increase ubiquitination of v-Src versus vehicle treatment, the signals was hardly detectable (Lane 2 and 3 in Figure 5C ). Alternatively, a proteasome inhibitor (lactacystin) was used to block the rapid degradation of ubiquitinated proteins for enhancing the signals. As shown in Lane 4 and 5 in Figure 5C , andrographolide treatment in the presence of lactacystin increased the ubiquitination of v-Src as compared with lactacystin treatment alone, suggesting that andrographolide facilitated the v-Src protein degradation via an ubiquitin-dependent manner.
Andrographolide-mediated inhibition of v-Src transformation is associated with the down-regulation of Erk1/2 signaling pathway -
The Erk kinase, PI-3 kinase and STAT-3 signaling pathways have previously been shown to be crucial for v-Src-induced transformation in different mammalian cell types (13, 14, 40) . However, the significance of the involvement of these pathways in v-Src-transformation of RK3E cells has not yet been reported. To further determine whether these signaling pathways are associated with the inhibitory effect of andrographolide, we compared the effects of several signaling inhibitors on v-Src transformation with that of andrographolide. For each inhibitor, multiple concentrations were examined for toxicity and only sub-lethal dosages were chosen for subsequent experiments. For those inhibitors blocking v-Src-mediated morphological transformation, cell morphology from the treatment at the lowest effective concentration is shown in Figure 6A . Conversely, for those drugs not blocking morphological transformation, cell morphology from treatment at the highest concentrations of doses examined is shown ( Figure 6A ). Our results indicated that PI3K inhibitor (LY294002) and STAT-3 inhibitor apparently did not block v-Src-mediated morphological transformation but MEK inhibitors (PD98059 and U0126) showed an inhibitory effect similar to that of andrographolide. We next examined the effects of andrographolide treatment on the activation of these signaling pathways. As shown in Figure  6B and 6C, both active Erk1/2 and Akt level were elevated in v-Src-transformed cells but strongly diminished after andrographolide treatment. On the other hand, STAT-3 was not significantly activated in v-Src-transformed RK3E cells and levels of active STAT-3 were not affected by andrographolide treatment (data not shown). The calpain-calpastatin proteolytic system has been previously demonstrated to participate in the v-Src-induced morphological transformation of chicken embryo fibroblasts (CEF) (12) . However, treatment with ALLN (an inhibitor of calpain-calpastatin proteolytic pathway) did not block the morphological changes of v-Src-transformed RK3E cells ( Figure 6A ). Taken together, our results suggest that down-regulation of the Erk signaling pathway plays a crucial role in the inhibition of v-Src-induced transformation by andrographolide. 
Constitutive active Erk signaling interferes with andrographolide-mediated inhibition of v-Src transformation -
DISCUSSION
Andrographolide is a lactone diterpenoid originally isolated from the Chinese herb Andrographis paniculata. In recent years, novel pharmacological effects of andrographolide have been identified, including anti-inflammation, anti-apoptosis, anti-angiogenesis and anti-cancer (22) (23) (24) (25) (26) . Nevertheless, it has never been reported that andrographolide inhibits the activity of the v-Src oncoprotein. In this study, we demonstrated that andrographolide blocks v-Src-mediated morphological transformation and anchorage-independent cell growth ( Figure 1 ). Andrographolide treatment leads to the degradation of v-Src protein via ubiquitination ( Figure 2B , Figure 2C and Figure 5 ), the attenuation of the phospho-Erk1/2 level ( Figure  6B ), the maintenance of actin organization (Figure 2A) , and the delay of E-cadherin down-regulation ( Figure 2B and Figure 2C) . Furthermore, v-Src-mediated protein-protein interactions are also affected by andrographolide (supplemented data Figure 2) . Although andrographolide alters the intracellular tyrosine phosphorylation pattern, it does not directly repress the v-Src kinase activity in vitro ( Figure  3) .
We speculate that the reduction in v-Src protein expression is the major event of the andrographolide-mediated inhibition of cellular transformation. Our data showed that andrographolide does not interfere with the transcription and translation of v-Src and we further demonstrated that andrographolide facilitates the degradation of v-Src protein through an ubiquitin-mediated pathway ( Figure  5 ). Noticeably, it has been described that andrographolide suppressed the expression of inducible nitric oxide synthase (iNOS) in macrophages (23) . However, andrographolide treatment does not cause general protein down-regulation, since the levels of several other proteins (including actin, β-catenin, E-cadherin, Erk and Akt) were not affected by andrographolide ( Figure 2B , Figure 2C and Figure 6 ). Many small-molecules are known to target multiple proteins (19) and we therefore cannot, at present, exclude the possibility that andrographolide may also act on other molecular targets in ts-v-Src cells.
According to our results, andrographolide treatment promotes the ubiquitination and degradation of v-Src protein.
The ubiquitin-proteasome system is responsible for most protein degradation in mammalian cells. Ubiquitination is mainly mediated by three major enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-protein ligase (E3) (41) . Since the Cbl protein, an E3 ligase, was known to cause ubiquitination and degradation of Src (42), it is possible that andrographolide facilitates the interaction of v-Src protein with Cbl. Alternatively, andrographolide may attenuate functions of the deubiquitylating enzyme, such as AMSH (associated molecule with the Src homology-3 domain of STAM), to promote protein ubiquitination by the E3 ligases (43) . Furthermore, accumulating reports suggest that Hsp90 and its co-chaperones play essential roles in the modulation of Src stability. The strong physical association between v-Src and Hsp90 was previously shown to be essential for the transformation activity of v-Src (44) (45) (46) . Two v-Src inhibitors, herbimycin A and radicicol, were known to directly perturb Hsp90 and preferentially destabilize v-Src over c-Src protein (37, 38) . Herein, we have observed that andrographolide specifically reduces v-Src protein level but not c-Src ( Figure 2C and Figure 4A ), similar to the two above-mentioned inhibitors.
We thus speculate that andrographolide might regulate v-Src protein via interfering with Hsp90-related functions.
Different signaling pathways have been reported to be crucial for v-Src-induced malignant transformation of different cell types. However, v-Src appears to induce malignant transformation via distinct signaling pathways in different cell types. For example, both the MAP kinase and PI3 kinase signaling pathways are required for transformation of chicken embryo fibroblasts (CEF) by v-Src (14) , but transformation of rat intestinal epithelial RIE-1 cells by v-Src is independent of MAPK activation (13) . Furthermore, activation of the STAT-3 (signal transducers and activators of transcription 3)-signaling pathway and calpain-calpastatin proteolytic system are essential for v-Src-mediated transformation of NIH3T3 cells and CEF cells, respectively (11, 12) . With respect to the v-Src-mediated transformation of RK3E cells in this study, our data demonstrated that both the Erk and PI3K signaling pathways are activated during v-Src transformation process ( Figure 6B and 6C) , but only the Erk signaling pathway is required for v-Src-induced morphological transformation ( Figure 6A ). Furthermore, calpain and STAT-3 are not activated in v-Src-transformed RK3E cells (data not shown) and neither ALLN nor STAT-3 inhibitor was able to block morphological changes of v-Src-transformed RK3E cells ( Figure 6A ). Taken together, these results support the hypothesis that activation of the Erk signaling pathway is mainly responsible for v-Src-induced morphological transformation of RK3E cells.
According to our data, andrographolide treatment remarkably diminished the activation of Erk1/2 and Akt ( Figure 6B and 6C ). Similar observations have been previously described in other cell types. Andrographolide treatment is known to abolish complement 5a (C5a)-induced macrophage recruitment through inhibition of Erk1/2 and Akt phosphorylation (47) . In the present study, although andrographolide inhibited both the Erk and PI3K-signaling pathways, only inhibition of the Erk pathway caused a non-transformed morphology ( Figure  6 ). Furthermore, expression of constitutive active MKK1 (the upstream activator of Erk signaling) abolished the andrographolide-suppressed morphological inhibition (Figure 7) . These results suggest that andrographolide blocks v-Src-mediated transformation mainly via inhibiting the Erk signaling pathway. Such inhibition may result from direct interference with Erk signaling or down-regulation of v-Src by andrographolide. We suspect that down-regulation of Erk signaling pathway is a consequence of andrographolide-induced v-Src degradation based on the following observations. Firstly, down-regulation of Erk activation correlates well with the reduction of v-Src expression/activation in time-course experiments ( Figure 2C and Figure 6 ). Secondly, Src-expressing cells with constitutive Erk activation are resistant to andrographolide (Figure 7 ), suggesting that this compound does not directly interfere with the Erk signaling pathway.
In summary, the results from the present study clearly demonstrate that andrographolide can inhibit v-Src-induced transformation via ubiquitin-dependent v-Src protein degradation and attenuation of the Erk-signaling pathway. Our findings provide evidence that andrographolide can exhibit anti-cancer activity by a novel mechanism involving the degradation of Src oncoprotein. To our knowledge, this is the first report to show possible antagonistic effect of andrographolide on v-Src. Whether andrographolide affects the activity or expression of other oncoproteins remains to be determined. Further studies to elucidate the effects of andrographolide on other cancer-related proteins should certainly provide crucial information about the anti-cancer mechanism(s) of andrographolide.
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